Experienced in Chronic Myelomonocytic Leukemia (CMML)

Herbert D. Spapen

Universitair Ziekenhuis Brussel
Brussels, BRU, BE 
Experienced in Chronic Myelomonocytic Leukemia (CMML)
Universitair Ziekenhuis Brussel
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Herbert Spapen practices in Brussels, Belgium. Mr. Spapen is rated as an Experienced expert by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Sepsis, Pneumonia, Metabolic Acidosis, Rhabdomyolysis, and Heart Bypass Surgery.

His clinical research consists of co-authoring 162 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Chronic Myelomonocytic Leukemia (CMML).

Gender
Male

Locations

Universitair Ziekenhuis Brussel
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III Randomised Controlled Trial of Continuous Beta-lactam Infusion Compared With Intermittent Beta-lactam Dosing in Critically Ill Patients
A Phase III Randomised Controlled Trial of Continuous Beta-lactam Infusion Compared With Intermittent Beta-lactam Dosing in Critically Ill Patients
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit
A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit
Enrollment Status: Completed
Publish Date: April 06, 2022
Intervention Type: Biological, Other
Study Drug: Cx611
Study Phase: Phase 1/Phase 2
A DB Four-Arm, Parallel Group, Proof of Concept, Dose-Finding Adaptive Phase 2a/2b RCT to Investigate the Safety, Tolerability and Efficacy and Effect on QoL of Human Recombinant Alkaline Phosphatase in Patients With Sepsis-Associated AKI
A DB Four-Arm, Parallel Group, Proof of Concept, Dose-Finding Adaptive Phase 2a/2b RCT to Investigate the Safety, Tolerability and Efficacy and Effect on QoL of Human Recombinant Alkaline Phosphatase in Patients With Sepsis-Associated AKI
Enrollment Status: Completed
Publish Date: March 23, 2020
Intervention Type: Other, Biological
Study Phase: Phase 2
View 2 Less Clinical Trials

162 Total Publications

Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study.
Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study.
Journal: Infectious diseases and therapy
Published: September 29, 2021

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Spapen's expertise for a condition
ConditionClose
      View All 29 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile